Guest: Jeffrey V. Matous, MD

The treatment landscape for Multiple Myeloma is continuing to rapidly evolve, which is why it’s important for healthcare professionals to stay up-to-date on all of the FDA-approved therapy options that are available, including triplets with POMALYST. Join Dr. Jeff Matous from the Colorado Blood Cancer Institute in Denver as he discusses a triplet with POMALYST® and the clinical trial that evaluated its efficacy and safety in patients with Relapsed/Refractory Multiple Myeloma.

This information is intended for US audiences only.

Dr. Matous was paid a fee by Celgene for his participation in this program.

POMALYST Indication

POMALYST® (pomalidomide) is a thalidomide analogue indicated, in combination with dexamethasone, for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.

POMALYST + dexamethasone + daratumumab Indication

POMALYST + dexamethasone + daratumumab is indicated for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.

Information about POMALYST + dexamethasone + daratumumab does not appear in the POMALYST Prescribing Information (PI). Please see ...